New strategies in the treatment and prevention of allergic diseases.
Allergic diseases (AD) are more prevalent today than 30 years ago but over the same period, few novel efficacious drugs have been discovered to treat, control or even cure these disorders. Topical or systemic glucocorticosteroids combined with symptom-relieving medications, such as beta 2 -adrenoceptor agonists, leukotriene inhibitors or antihistamines, are still the mainstay of antiallergic treatment. Modified glucocorticosteroids with less adverse effects, better bronchodilators and new selective mediator inhibitors may improve symptom control in the future. Only specific immunotherapy has shown potential for long-lasting disease-modifying effects. Immunomodulation is a therapeutic goal, aiming to modify the dominant helper T cell Type 2 inflammation to a helper T cell Type 1 response using modified allergens, mycobacteria or CpG oligodeoxynucleotides. Humanised monoclonal anti-IgE antibodies are an exciting new immunomodulatory medication that are expected to reach the clinical practice and have recently been licensed in Australia and the US. Advances in molecular, cellular and genetic research of the immunopathophysiology of AD have led to the development of new antagonists for cytokines, chemokines, receptors, second messengers and transcription factors that may become available for clinical use in the next 10 years. Specific diets supplemented with antioxidants or probiotics need further study but offer promise as safe and cheap preventative medicine. The strong genetic component of AD and the Human Genome Project have opened a new field of research, and modification or replacement of target genes has a curative potential with exciting new therapeutic developments in the years ahead.
Haitchi
Hans Michael
HM
University of Southampton, School of Medicine, Southampton General Hospital, Southampton, UK. H.M.Haitchi@soton.ac.uk
Holgate
Stephen T
ST
D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use; D001993:Bronchodilator Agents / Q000494:pharmacology / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic; D015316:Genetic Therapy / Q000379:methods / Q000639:trends; D006801:Humans; D006967:Hypersensitivity / Q000145:classification / Q000517:prevention & control* / Q000628:therapy*; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D018377:Neurotransmitter Agents / Q000037:antagonists & inhibitors / Q000494:pharmacology / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D001993:Bronchodilator Agents; D007166:Immunosuppressive Agents; D018377:Neurotransmitter Agents